Inventurus Knowledge Solutions Buys Turbo Health for $500,000
Key highlights
- IKS acquired 100% of Turbo Health Holdings, LLC for $500,000 in cash on November 10, 2026.
- Turbo Health was incorporated in the United States on November 5, 2026 and had no prior three-year turnover record.
- The target holds certain transferred client contracts in an ambulatory revenue cycle management segment.
- IKS completed its separate $557 million acquisition of TruBridge, Inc. on July 9, 2026.
powered by IRIS

Inventurus Knowledge Solutions Limited acquired 100% of US-based Turbo Health Holdings, LLC for $500,000 in cash, completing the transaction on November 10, 2026. The purchase gives the company a healthcare technology entity associated with transferred client contracts in the ambulatory revenue cycle management business.
Know Inventurus Knowledge Solutions inside out
Results, valuation, peers and who's buying, in one view.
What did Inventurus Knowledge Solutions acquire from Turbo Health?
Inventurus Knowledge Solutions Limited, through its wholly owned material US subsidiary Inventurus Knowledge Solutions, Inc., acquired the entire shareholding of Turbo Health Holdings, LLC. IKS Inc. approved the purchase on November 9, 2026, US time, and completed the acquisition after executing the relevant agreements on November 10.
Turbo Health is a newly incorporated US healthcare technology entity. The company was incorporated on November 5, 2026, according to the disclosure, and therefore had no turnover record for the preceding three years. IKS said certain client contracts had been transferred to the target entity, which operates in a segment of Optum Insight's ambulatory revenue cycle management, or RCM, business.
The consideration was $500,000, paid entirely in cash. The filing did not mention share consideration, deferred payments, an earnout, or any other contingent payment. It also did not name the seller or specify the individual client contracts transferred to Turbo Health.
How was the Turbo Health acquisition completed?
The Turbo Health acquisition was completed by IKS Inc., the US-based wholly owned material subsidiary of IKS. Its board approved the transaction a day before the announced completion date, and IKS disclosed the outcome to the National Stock Exchange of India and BSE under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations.
The disclosure stated that no governmental or regulatory approvals were required for the transaction. It also stated that the acquisition was not a related-party transaction and that IKS's promoter and promoter group had no interest in the entity being acquired.
The structure gives IKS full ownership of Turbo Health rather than a minority investment or commercial partnership. As the target is newly incorporated, the announced price primarily relates to the entity and the client contracts transferred to it, rather than a record of reported historical operations or revenue.
Got a follow-up? Ask IRIS
Why is Turbo Health relevant to IKS's healthcare business?
Turbo Health is relevant because it adds a US healthcare technology platform and transferred client contracts connected to ambulatory RCM services. RCM covers administrative and technology processes supporting the movement of healthcare claims and payments, making it a core operating area for healthcare technology service providers.
IKS said the acquisition is intended to expand its market reach and strengthen solutions for healthcare clients. The disclosed transaction is relatively small at $500,000, but its relevance lies in the contracts and business segment identified in the filing rather than in the target's historical financial performance, which was unavailable due to its recent incorporation.
The purchase follows a larger expansion of IKS's US operations during 2026. On July 9, 2026, IKS Inc. completed the acquisition of TruBridge, Inc. for $557 million through a merger involving IKS Next Horizon, Inc. TruBridge became a wholly owned subsidiary of IKS Inc. following that transaction.
IKS also incorporated Value Partners Collective ACO, LLC in the US to participate in a federal healthcare programme. Separately, an IKS subsidiary invested $2.84 million in IKS WWMG MSO LLC, taking its stake to 51.88% and resulting in the entity being consolidated as a subsidiary.
How does the deal affect IKS investors and operations?
The Turbo Health transaction adds a fully owned US entity to IKS's operating structure, with no stated requirement for regulatory consent. For investors, the immediate financial commitment disclosed is limited to $500,000 in cash, while the filing provides no financial forecast, revenue estimate, or profitability guidance for the acquired business.
The absence of historical turnover means the disclosure does not permit a comparison between the purchase price and Turbo Health's prior sales. It also means investors do not have reported financial data on the target's earlier performance. The company has instead described the business in terms of healthcare technology, transferred client contracts, and its position within an ambulatory RCM segment.
The deal sits alongside IKS's broader US expansion, including the much larger TruBridge acquisition. That earlier transaction was financed through arrangements involving IKS and IKS Inc., with financing and security agreements executed in July 2026. The Turbo Health acquisition notice does not link the $500,000 purchase to those financing facilities.
For industry participants, the transaction indicates IKS's continued focus on US healthcare technology and RCM-related capabilities. However, the company has not disclosed the number of contracts involved, customer identities, expected integration timelines, or the expected financial contribution from Turbo Health.
Conclusion
IKS has acquired 100% of Turbo Health for $500,000 in cash, adding a newly formed US healthcare technology entity with certain transferred ambulatory RCM client contracts. The transaction expands the company's US healthcare operating footprint while carrying a modest disclosed cash consideration compared with its $557 million TruBridge acquisition.
Investors will watch for future disclosures on Turbo Health's operational integration, the nature and scale of the transferred contracts, and any financial contribution to IKS's consolidated results. The November 10 filing did not provide performance targets, revenue guidance, or a timetable for these developments.


